Trial Profile
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD) In Patients With Fulminant Hepatic Failure (FHF)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2013
Price :
$35
*
At a glance
- Drugs Extracorporeal hepatocyte-based therapy (Primary)
- Indications Liver failure
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vital Therapies
- 07 Dec 2013 New trial record